Will The $3bn Stimulus Amid COVID-19 Place Indian Cos Among Goliaths?
INR 51bn Investments Committed Under First PLI Scheme
Executive Summary
Following an INR69bn incentive scheme for APIs, the Indian government has come up with an INR150bn scheme for formulations and more. Will this $3bn push prove to be the one that companies like Sun Pharma and Aurobindo, currently at 36 and 48 respectively in Scrip 100 rankings, need to break into the top league?
You may also be interested in...
India’s Interim Budget Pushes Innovation, Green Production, HPV Vaccination
India’s interim budget 2024 hikes allocation for production-linked incentive schemes in pharmaceuticals, supports biotech start-ups - particularly green ones- and sets the right note for inclusion of HPV vaccination in the country’s Universal Immunization Program, one of the world's largest public health programs. How does it help?
Late To The Antibody-Drug Conjugate Party, But Will 2024 Be A Turning Point For India?
In 2024, Sun Pharma’s ADC candidate is expected to be in human trials, while CDMOs like Piramal Pharma Solutions and Aurigene are to operationalize significant new capacities. But can India compensate for a late start on the ADC journey by tapping low development costs and favorable policies, or is it too little with China far ahead in the race?
Is The US Less Attractive Than India? A Proxy Comparison Via Strides And Torrent
Scrip examines Torrent Pharma and Strides Pharma’s divergent strategies and Q4 financial performance in the US and India while presenting an infographic to compare market-wise metrics